Both in the wild as well as on plantations, Indian sandalwood is an extremely demanding tree.
Because the tree places such high demands on the availability of appropriate host plants, fertile soils, appropriate climate as well as an adequate supply of fresh water, its cultivation is very time and research intensive and therefore costly. Without corresponding know-how, it is not possible to successfully grow Indian sandalwood.
Our asset partner Quintis not only has a unique expertise in the cultivation of Indian sandalwood on its own plantations, but also in the downstream processing of the tree into sandalwood oil, and moreover, is the world’s sole supplier of pharmaceutical grade Indian sandalwood oil (which Quintishas branded SAO).
It is estimated, that Quintis has a know-how lead over its competitors relating to the cultivation, processing and the marketing of Indian sandalwood of at least 15 years.
Quintis continuous to invest significantly into the costly research and development to optimize the growing of its own seedlings, the management of its own plantations, as well as the processing of the tree into its many by- as well as end-products.
The know-how lead which Quintis has built-up in recent decades constitutes a major barrier-to-entry for potential competitors into the market for Indian sandalwood trees and products.
The lucrative and rapidly emerging new market for pharmaceutical applications of Indian sandalwood will also remain very difficult for potential competitors to gain access to, as Santalis, a 100% subsidiary of Quintis (which continues to be the world’s sole supplier of pharmaceutical grade Indian sandalwood oil, i.e. SAO) holds the world’s exclusive rights to market SAO in the healthcare sector.
Learn more about Quintis’s end-to-end processes from plantation to marketing of finished end-products in the following section “Value Chain“.